2022
844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody
Larkin J, Dalle S, Sanmamed M, Wilson M, Hassel J, Kluger H, Orloff M, Weber J, Finckenstein F, Hari P, Jagasia M, Yin H, Shi W, Sulur G, Wu X, Gontcharova V, Lewis K. 844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody. Annals Of Oncology 2022, 33: s935-s936. DOI: 10.1016/j.annonc.2022.07.970.Peer-Reviewed Original Research
2012
Immunotherapy for metastatic melanoma
Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. Journal Of Cellular Biochemistry 2012, 113: 725-734. PMID: 22006439, DOI: 10.1002/jcb.23402.Peer-Reviewed Original ResearchConceptsMetastatic melanomaPromising investigational approachesTreatment of melanomaImmunogenic tumorsAntitumor immunityCTLA-4Interleukin-2First cytokineInvestigational approachesProlonged responseMelanomaMonoclonal antibodiesImmunotherapyTreatmentIpilimumabPatientsCytokinesTumorsSmall subsetDiseaseImmunityAntibodies